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1. Introduction 
The application of gene therapy in the field of Urology is not limited to cancer therapy but is 
also being evaluated for non-cancer related bladder dysfunctions as well as erectile 
dysfunction (ED). This article will review the use of gene therapy for these conditions; the 
vectors used and limitations associated with different gene delivery systems and the 
attempts to overcome these shortcomings.  
2. Bladder cancer 
Bladder cancer is the 7th most common cancer worldwide. It has a natural history of 
superficial recurrences and local progression. It is estimated that within 18 months of first 
diagnosis approximately 50% of patients will have a recurrence (Anderson & Naish 2008). 
Thus there is a need for frequent monitoring of these patients. In the US the estimated life-
time cost of therapy for bladder cancer patients with non-muscle invasive disease was US 
$21.03 million  based on a Medicare database (Cooksley et al. 2008). The majority of this is 
spent on surveillance and the treatment of recurrences. Tumors occur on the luminal surface 
of the bladder and the architecture of the bladder permits topical intravesical therapies. The 
bladder is isolated from other organs and tissues and intravesical therapy permits contact 
with the entire internal surface of the bladder with minimal systemic side-effects.  
The present gold standard therapy for superficial bladder cancers is immunotherapy with 
Mycobacterium bovis, Bacillus Calmette Guerin (BCG) following local transurethral 
resection of the bladder tumor (TURBT). BCG induces a mononuclear and neutrophilic 
infiltrate in the bladder wall which results in an inflammatory response as measured by 
cytokine production that causes sloughing of both tumor and normal cells (Herr and 
Morales 2008).  The presence of IL-2, IL-8 and IL-18 in the urine of patients has been 
reported to correlate with response to therapy (Thalmann et al. 1997; Thalmann et al. 2000; 
Saint et al. 2003). Unfortunately, BCG has several shortcomings: it is a live vaccine and 
commonly causes side effects and occasionally septicemia. In addition some patients (20-
42%) do not respond to therapy (Kamat and Lamm 2000).  In place of BCG, recombinant 
cytokines such as IFN-γ, TNF-α, and IL-2 have been used in a number of clinical trials with 
encouraging results (Glazier et al. 1995; Den Otter et al. 1998; Stavropoulos et al. 2002). 
However, recombinant cytokines are costly, unstable in urine and have poor permeability 
www.intechopen.com
 Gene Therapy Application 
 
244 
across the glycosaminoglycan (GAG) layer of the urothelium.  Gene therapy is a natural 
alternative approach to ensure cytokine production in the bladder environment. 
2.1 Viral transfection systems for bladder cancer 
Initially replication defective viruses were generated with the sole purpose of gene delivery 
(Thomas et al. 2003). The viruses evaluated included: Adenovirus (type 2 and 5), Adeno-
associated virus (Parvoviridae family), Herpes simplex virus, Retrovirus (Dumey et al. 2005), 
Canary pox virus and Vaccinia virus (Lee et al. 1994). Table 1 lists their characteristics.  
However, because of the limited transduction capability of some viruses, replicating and 
conditionally replicating viruses were developed. These viruses amplify the transfection 
efficiency, as virus transduced cells produce more viruses that can infect the surrounding 
cells. Replication of wild type viruses also induces cytolysis of infected cells.  
2.1.1 Limitations and Improvements  
2.1.1.1 Non-specificity of transfection 
Siemens et al. compared adeno-, canary pox and vaccinia viruses in terms of their ability to 
transfect tumor cells after intravesical delivery in a murine model of bladder cancer 
(Siemens et al. 2003). The vaccinia and avian pox viruses were better at transfecting tumor 
cells than adenoviruses but all three resulted in transfection of extravesical tissue (e.g. 
kidney, liver, spleen). In contrast Wood et al reported only sporadic extravesical transfection 
after intravesical adenovirus instillations (Wood et al. 1999).   
To reduce non specific viral transduced gene expression, oncolytic adenoviruses have been 
engineered to express the E1A and E1B genes under the control of the uroplankin II gene 
promoter (Zhang et al. 2002; He et al. 2009) which limits expression to urothelial cells. 
Another strategy to target viral replication to tumor cells is to place the adenovirus E1A 
gene under the control of the telomerase promoter (Lanson et al. 2003), the midkine gene 
promoter (Terao et al. 2007) or the Cox-2 promoter  (Shirakawa et al. 2004). All these genes 
are highly expressed in tumor cells.  
Bladder cancer cells often over-express the epidermal growth factor receptor (EGFR) and 
targeting EGFR with bi-specific antibodies improved the delivery of adenovirus to cancer 
cells (van der Poel et al. 2002). A gammaretrovirus carrying a chimeric envelope protein 
containing a single chain variable fragment (scFv) antibody to the human epidermal growth 
factor receptor 2 (HER2) was shown to specifically target cells expressing Her2 (Tsai et al. 
2010).  
2.1.1.2 Transfection efficiency  
The internal surface of the bladder is covered by uroplakin proteins and the GAG layer 
which together provide a barrier to transfection of urothelial cells. Agents that disrupt this 
protective layer such as ethanol, HCl, dodecyl-B-d-maltoside and sodium dodecyl sulphate 
have been shown to improve viral transduction of the bladder (Engler et al. 1999; Lin et al. 
2002; Ramesh et al. 2004). 
Though adenoviruses are the most popular viruses for gene therapy they require adhesion 
with the cellular coxsackie-adenoviral receptor (CAR) for transduction of mammalian cells. 
Neoplastic tissue unlike normal bladder cells have reduced CAR expression (Buscarini et al. 
2007)  as a result of epigenetic control mechanisms (Pong et al. 2003).  
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Table 1. Characteristics of viral vectors for gene therapy 
To circumvent the need for receptor mediated uptake, polymers have been used to enhance 
adenovirus transfection of bladder cells (Kasman et al. 2009) or even small molecule 
excipients such as Syn3 (Connor et al. 2001; Yamashita et al. 2002; Nagabhushan et al. 2007). 
A recent study has shown that CAR receptor expression and thus adenoviral expression can 
be increased by treatment with histone deacetylase inhibitors (HDACI) such as trichostatin 
A and sodium phenylbutyrate (Sachs et al. 2004). 
2.1.1.3 Previous Immunity 
Vaccinia viruses have long been used in man as vaccines against smallpox. This raised the 
issue of whether previous immunization would block the effectiveness of these viruses as 
gene delivery vehicles. Intravesical instillation of vaccinia viruses was successfully 
demonstrated in pre-immunized mice (Lee et al. 1994). The immunogenicity of adenoviruses 
is a major limitation in most therapeutic strategies. However it may be advantageous in 
bladder cancer therapy where non-specific inflammation as a consequence of BCG 
instillation has been associated with tumor removal.  
2.1.1.4 Promoter inactivation  
Adenovirus genes expressed from a CMV promoter induced better gene expression than 
those expressed using a RSV promoter (Freund et al. 2000). But quite often the CMV 
promoter is inactivated in vivo. It has been found that adenoviral transfection together with 
HDAC inhibitor trichostatin or retinoic acid improved CMV promoter activity. Treatment 
with these drugs could improve and prolong adenoviral transgene expression (Gaetano et al 
2000). The development of tissue specific promoters as described above may resolve this 
problem.  
2.2 Non-viral transfection systems for bladder cancer 
The strength and weakness of non-viral vectors is the transient expression of the delivered 
genes. For non-viral gene delivery the genes are encoded on plasmid DNA of bacterial 
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origin. Non-viral delivery agents include liposomes (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium chloride, DOTAP), polyethylenimine (PEI), viral envelopes (with 
fusogenic properties)  conjugated to liposomes (Hemagglutinating Virus of Japan (HVJ) 
liposomes), chitosans as well as physical means such as the use of an electrogun or 
ultrasound (Harimoto et al. 1998; Lawrencia et al. 2001; Ogawa et al. 2004; Bonnet et al. 2008; 
Tsai et al. 2009; Zaharoff et al. 2009).  Plasmid DNA delivery systems result in cellular entry 
via the endosomes (Al-Dosari & Gao 2009). Endosomal escape is often difficult and when 
successful the plasmid DNA is mainly restricted to the cytoplasm. A small amount may 
make it to the nucleus and exist as episomal DNA molecules that can be lost during 
replication (Al-Dosari & Gao 2009).  Besides the delivery agents, the plasmid DNA sequence 
can also modulate the efficiency of transfection as discussed below.  
2.2.1 Limitations and Improvements 
2.2.1.1 Promoter inactivation 
It has been reported that the CMV promoter often used for plasmid gene expression does 
not always result in good gene expression (Loser et al. 1998) as a consequence of promoter 
inactivation.  This can be overcome by using a HDAC inhibitor, as demonstrated with OSU-
HDAC42 (Lai et al. 2010). An alternative strategy is to utilize tissue/cancer cell specific 
promoters such as the COX-2, H19 and human IGF2-P4 gene promoters (Ohana et al. 2002; 
Zhang et al. 2008; Amit & Hochberg 2010).  
2.2.1.2 Transfection efficiency 
The primary focus of improving plasmid DNA transfection is improving escape from the 
endosomes and this is achieved by developing new additives and lipoplexes or even 
polyplexes that use either acidification or osmotic pressure changes or membrane fusogenic 
molecules to allow DNA escape (Al-Dosari and Gao 2009). We developed a formulation 
comprised of DOTAP and Methyl-β-cyclodextrin solubilized cholesterol (MBC) that 
transfects urothelial cells in vivo within 2 hours of exposure. Transfection was confined to 
the bladder (Lawrencia et al. 2001) and occurred in the superficial and deeper layers of the 
urothelial tumours (Wu et al. 2003).  
2.2.1.3 Specificity of plasmid expression and activity/duration 
Antibodies have been used to target delivery of plasmids to tumor cells. ScFv antibody to 
Her-2 (Tsai et al. 2009) or transferrin have been demonstrated to successfully target plasmids 
to tumor cells (Pirollo et al. 2008). The latter strategy targets both primary and metastatic 
disease when delivered systemically.  Targeting of plasmid DNA to the nucleus can also be 
induced by introducing mammalian transcription factor binding sites in the plasmid and 
this increased the duration of expression (Gill et al. 2009).  
Plasmid DNA expression is transient because of the episomal nature of transfected DNA. In 
bladder cancer therapy this can be overcome by repeated intravesical instillations. Another 
strategy to improve gene expression is to add a scaffold matrix attachment region (S/MAR) 
to the plasmid DNA. S/MAR serve both to ensure prolonged gene expression, by reducing 
the silencing of plasmid DNA as well as to ensure plasmid DNA replication as episomes 
(Gill et al. 2009).  
Integration of plasmid DNA into chromosomal DNA is achievable now. The techniques 
used include retroviral integrase (Tanaka et al. 1998), sleeping beauty (SB) transposons 
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(Hackett et al. 2010) or phage recombinase mediated integration (Olivares et al. 2002). Thus 
in the future a single intravesical instillation may be sufficient for prolonged therapeutic 
effects.  
2.2.1.4 Liposome free delivery 
For small molecules such as CpG oligodeoxynucleotides (ODN), intravesical delivery to 
urothelial cells can be achieved without a transfection agent (Ninalga et al. 2005). But 
plasmid DNA requires a delivery agent. Nanoparticles (10-100nm in size) with bound 
plasmid DNA are recognized by cell surface nucleolin on HeLa cells and this  
results in DNA transport to the nucleus (Chen et al. 2008) and avoidance of endosomal 
entrapment.  
2.2.1.5 Inflammation 
The CpG sequences on plasmid DNA induce inflammation that could reduce gene 
expression by either destruction of transfected cells or promoter inactivation (Yew et al. 
2000). Minicircle DNA (mcDNA), are supercoiled DNA with only the therapeutic gene 
cassette. They are generated in vivo by site specific recombination in E coli and exhibit 
improved gene expression in terms of the level and duration of gene expression  (Darquet et 
al. 1997).   
2.3 Preclinical evaluation of genes and evolving gene therapy strategies  
The different categories of genes used successfully in animal studies are listed in Table 2. 
Both Sub-cutaneous (sc) and orthotopic models of bladder cancer have been used to 
evaluate gene therapy. While the data from sc studies have shown the efficacy of the 
expressed genes, it is the orthotopic models that best reflect clinical disease and therapeutic 
gene delivery. In general regardless of the delivery system or gene delivered tumor growth 
reduction or even eradication has been reported in murine models of bladder cancer.  Most 
therapeutic schedules used in the animal studies require repeated instillations of the gene 
delivery vehicle whether it is a viral or non-viral vector. However, a recent study of viral 
gene delivery of IFNα indicated that a high dose could reduce the need for increased 
intravesical instillations (Tao et al. 2006). Transfection using transposons may also reduce 
the need for repeated transfection of plasmid DNA. 
New therapies aim to combine several strategies at once.  These include the use of oncolytic 
viruses and immune modulation using GMCSF (Cozzi et al. 2001; Ramesh et al. 2006); wild 
type p53 and ribozyme erb-2 (Irie et al. 2006) and Rb94 or oncolytic viruses and 
chemotherapeutic drugs (Zhang et al. 2002; Pirollo et al. 2008).  In vitro studies have shown 
that combining AdHSVTK, ganciclovir and chemotherapy may have therapeutic benefit 
(Freund et al. 2003). Further the beneficial effect of 5-FU and adenovirus cytosine deaminase 
gene therapy could be enhanced by irradiation (Zhang et al. 2003). Such multi-factor 
therapies may be better at eradicating tumor cells.  Another strategy is to modify immune 
cells in vitro for cancer therapy. Dendritic cell manipulation by transfection with adenovirus 
carrying the survivin gene has been shown to induce cytotoxic T lymphocytes ( CTLs) 
(Kikkawa et al. 2009).  
2.4 Gene therapy clinical trials  
Table 3 lists several Phase I trials that have been carried out for bladder cancer. However, 
results from only a few of these trials are published. 
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Table 2. Genes demonstrated to cause tumor reduction in murine models of bladder  
cancer. 
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Table 3. Clinical trials for bladder cancer gene therapy. NCT designation indicates data 
obtained from http://www.who.int/ictrp/en/;  
Other alphabet and number designations are for data obtained from  
http://www.wiley.com/legacy/wileychi/genmed/clinical where the alphabets indicate 
country of registration and the numbers only designation are for data obtained from 
http://www.gemcris.od.nih.gov/Contents/GC_HOME.asp . Note some trials were 
registered on more than one web-site. 
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Information about completed, on-going and planned trials were obtained from the 
following sources: gene therapy clinical trials world wide web-site http://www.wiley.com 
/legacy/wileychi/genmed/clinical/; the clinical trials.gov, US National Institutes of Health 
and the Genetic Modification Clinical research Information System database 
http://www.gemcris.od.nih.gov/Contents/GC_HOME.asp and the World Health 
Organization International Clinical Trials registry platform portal http://www.who.int 
/ictrp/en/.  
A Phase I trial on vaccinia virus instillation showed increased lymphocyte recruitment and 
the induction of an inflammatory response in the bladder (Gomella et al. 2001). There were 
no clinical manifestations of vaccinia toxicity indicating the safety and therapeutic potential 
of this virus as a gene therapy vector. Adenovirus delivery of p53 was also shown to 
successfully deliver p53 gene to bladder cells but there was no change in 
immunohistochemical detection of p53 in bladder tissue (Pagliaro et al. 2003). However, 
adenovirus therapy was safe and well tolerated (Pagliaro et al. 2003). Delivery of adenovirus 
carrying p53 with a transduction enhancing agent improved p53 gene delivery and protein 
expression was found in patient tissue samples (Kuball et al. 2002). Though higher doses of 
the virus were administered, no dose toxicity was observed (Kuball et al. 2002). Similarly no 
serious adverse effects were reported by Malmstrom et al. from a recently concluded Phase 
I/IIa trial using AdCD40L (Malmstrom et al. 2010). They observed gene transfer in biopsies 
and the infiltration of T lymphocytes (Malmstrom et al. 2010). 
A plasmid was used to deliver the diphtheria toxin gene under the control of the H19 gene 
regulatory sequence in a Phase I/IIa trial for non–muscle invasive bladder cancer (Sidi et al. 
2008). They reported mild toxicity and observed complete and partial response in some 
patients. Thus based on these Phase I trials, both non viral and viral vectors appear to be 
well tolerated in man.  
Several new trials are either in progress or about to commence. These use non-viral and 
viral delivery vectors as listed in Table 3. A proposal for a Phase I trial for intravesical 
therapy in bladder cancer patients using plasmid DNA carrying the IFN-α gene and our 
liposome based delivery system is being evaluated by the Health Sciences Authority, 
Singapore.  
2.5 Other urological malignancies 
Though not covered here several clinical trials are on-going, evaluating gene therapy for 
prostate and renal cancers. In general the vectors and genes used are similar though tissue 
specific promoters may differ. Information on these trials can be obtained from the web-sites 
listed above. Unlike bladder cancer however, gene delivery to these tissues is not as simple. 
Thus tissue specific targeted gene expression has been developed. Another strategy is the 
use of macrophages transfected ex vivo with a plasmid carrying the E1A/B construct under 
the control of the hypoxia response element (HRE) as well as a replication competent 
adenovirus with the E1A under the control of the prostate specific antigen promoter. At the 
hypoxic tumor site the E1A protein is produced and the adenoviruses released infect tumor 
cells and cause their lysis (Muthana et al. 2011). Such a strategy prevents virus 
neutralization in vivo. 
3. Non-cancer related urological problems  
The bladder is made up of a reservoir and an outlet (bladder neck, urethra and urethral 
sphincter) whose activities are controlled by smooth and striated muscles. There are more 
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patients with bladder dysfunctions related to its primary function of urine storage and 
voiding than cancer. These include: lower urinary tract symptoms (LUTS), interstitial 
cystitis (IC), overactive bladder (OAB), spinal cord injuries affecting micturition and urinary 
incontinence (UI).  It is estimated that by 2018, some 2.3 billion people worldwide will be 
affected by at least one LUTS, OAB, UI and LUTS suggestive of bladder obstruction (Irwin 
et al. 2011). LUTS is an umbrella term that encompasses urine storage (increased  frequency, 
at least one episode of nocturia per night, urgency and UI), voiding and post-micturition 
symptoms (Abrams et al. 2003). Another urological problem is erectile dysfunction (ED).  
Both LUTS and ED are increased with aging and in patients with diabetes (Brown et al. 
2005). With the worldwide increase in the incidence of diabetes the incidence of these 
urological problems will increase.   
Most current therapies for the above mentioned conditions are palliative rather than 
therapeutic. Gene therapy however, may provide a way to cure the disease and the recent 
review by Christ  lists some of these strategies (Christ 2011).  Most of the bladder related 
problems seem to be linked to muscle and neuronal defects and because of the latter the 
most common vectors used for animals studies of bladder dysfunctions are HSV vectors. 
3.1 Urinary incontinence 
Urinary incontinence is a general term used to cover three types of incontinence namely 
stress, urge and overflow (Chancellor et al. 2001).  Stress incontinence occurs when the 
urinary sphincter muscle is unable to prevent urine leakage following jumping or coughing.  
This is more common in women than men. Treatment approaches include exercise, surgery 
and collagen injections into the sphincter muscle. Often multiple injections are required 
which adds to the cost of treatment and some patients are allergic to bovine collagen.  Tissue 
engineering and ex vivo gene therapy are alternative therapeutic strategies that are being 
evaluated (Shokeir et al. 2010).  Phase I trials of the delivery of autologous myoblasts and 
fibroblasts from muscle biopsies to female patients with stress incontinence have shown 
some benefit (Mitterberger et al. 2007). In mice, combining myoblast and gene therapy such 
as the ex vivo transformation of myoblasts with the VEGF gene resulted in improved 
volume and function of muscle cells (Delo et al. 2008). 
Urge incontinence is characterized by increased urinary urgency and frequency caused by 
involuntary bladder contractions leading to uncontrollable urine leakage. One study has 
evaluated intravesical non-viral delivery of a cDNA for the K+ channel and showed that this 
resulted in increased K+ channels in the smooth muscle of the bladder and amelioration of 
bladder overactivity (Christ et al. 2001).   
Overflow incontinence results from nerve damage such that patients cannot urinate. One 
common cause is diabetes related neuropathy. Diabetes related cystopathy is often 
irreversible and restoring bladder functions to diabetic patients is difficult  (Sasaki et al. 
2002). Animal studies have identified nerve growth factor (NGF) as a good candidate for 
gene therapy for diabetes induced incontinence (Apfel et al. 1994).  HSV delivery of NGF 
increased NGF in the bladder wall and dorsal root ganglion and improved voiding function 
in streptozotocin (STZ) induced diabetic rats (Goins et al. 2001; Sasaki et al. 2004).   
3.2 Interstitial cystitis/painful bladder syndrome 
Interstitial cystitis or painful bladder syndrome occurs predominantly in females (Persu et 
al. 2010). It is believed to result from underlying inflammation in the bladder. It cannot be 
adequately treated by drugs and prolonged drug therapy can lead to dependency and 
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tolerance to drugs that may require dose escalation to remain effective. Thus it is a candidate 
for gene therapy. Delivery of the preproenkephalin gene by HSV (Yokoyama et al. 2009)  has 
been shown to be beneficial in reducing pain.  A HSV vector carrying the ionotropic glycine 
receptor (GlyR) whose expression was induced by glycine had an analgesic effect (Goss et 
al. 2011). This vector when inoculated into the bladder wall of an inflammation model of 
IC/PBS in rats was activated by systemic glycine delivery. 
3.3 Overactive bladder 
Overactive bladder (OAB) is defined as “urinary urgency, usually accompanied by 
frequency and nocturia, with or without urgency urinary incontinence” (Haylen et al. 2010)  
Detrusor over activity is considered a single marker for OAB. It can occur as a result of 
spinal injury and could result in a lack of control of micturition. This has been demonstrated 
in animal models of spinal injury. HSV vector delivery of glutamic acid decarboxylase has 
shown benefit in a rat model of spinal injury (Miyazato et al. 2009; Miyazato et al. 2010). 
3.4 Erectile dysfunction 
Approximately 150 million men are projected to suffer from ED and the incidence of ED 
increases with age. Normal erectile function occurs as a result of 3 synergistic events 
namely: neurological mediated penial arterial inflow increase; cavernosal smooth muscle 
relaxation and restriction of venous outflow from the penis (Andersson & Wagner 1995). In 
ED one or more of these events may be impaired.  The penis is an excellent candidate for 
gene therapy because it is easily accessible, has limited blood flow and a slow cellular 
turnover (Bivalacqua & Hellstrom 2001). Though therapy is available for erectile 
dysfunction there are a significant number of patients who do not respond to available 
therapy (Yoshimura et al. 2010). The recent review by Harraz et al. provides an excellent 
overview of gene therapy strategies used in animal models of ED that have been shown to 
resolve this problem (Harraz et al. 2010).  Rather than reproducing that information only 
recent publications not included in that review are mentioned here. Over expression of the 
transient receptor potential (TRP) channels  6 (dominant negative)  by transfection with a 
plasmid caused a decrease in calcium  levels in the corporal smooth muscle and improved 
erectile function in diabetic rats (Jung et al. 2010).  Using a STZ induced diabetes model to 
evaluate erectile dysfunction, it was found that implantation of mesenchymal stem cells 
transfected with VEGF improved erectile function compared to implantation of 
mesenchymal stem cells alone (Qiu et al. 2011). 
3.5 Clinical trials 
Only two clinical trials are listed on the http://www.gemcris.od.nih.gov/Contents 
/GC_HOME.asp for urological conditions unrelated to cancer.  One is the Phase I trial for 
ED and the other is a trial for overactive bladder syndrome. Both trials used plasmid DNA 
carrying the calcium activated potassium channel (Melman et al. 2007). The results of the 
Phase I trial for ED indicate the safety of this delivery system. 
4. Major issues and future prospects for gene therapy 
One major issue is the safety of gene therapy in terms of its impact on the environment as 
well as long term safety in patients. Schenk-Braat et al found that only half of all registered 
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clinical trials included viral shedding data (Schenk-Braat et al. 2007) and what data was 
available was primarily for the time after virus delivery and not at the time of delivery. 
These questions should also be raised for plasmid based gene therapy. Long term follow-up 
data on patients who have received gene therapy may further ameliorate the safety concerns 
of this therapy. This will result in gene therapy being more readily applied to other non-
malignant conditions. The development of better plasmids and ways to integrate plasmids 
into the chromosome may lead to the greater use of plasmid rather than viral vectors for 
urological gene therapy. 
MicroRNAs (MiRNA) are new targets for cancer therapy. These are small non-coding RNA 
molecules that bind to complementary sequences in the protein coding regions of mRNA 
and block their translation. Their expression levels vary in cancer and normal tissues (Catto 
et al. 2011). MiRNA-203 and MiRNA-221 have been shown to modulate the growth and 
apoptosis of human bladder cancer cell lines (Lu et al. 2010; Bo et al. 2011) and these could 
be new targets for therapy.  Given the function of miRNA it is possible that these molecules 
could also be targets for non-cancer related bladder dysfunctions. This has not yet been 
explored and identifying such molecules may improve our knowledge of the development 
of these conditions. 
5. Conclusion 
The application of gene therapy for urological conditions is being evaluated in many 
preclinical disease models.  In general the results obtained are encouraging and soon these 
therapies may move to Phase I trials.    
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